文献速递白血病造血干细胞移植与细胞治疗

儿童急性髓系白血病首次异基因造血干细胞移植后复发结局:I-BFM 333例回顾分析

Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
PubMed 文献 · Br J Haematol · 2020-02-03

该回顾性I-BFM分析纳入333例首次异基因造血干细胞移植后复发的儿童急性髓系白血病患者。4年总生存概率为14%;

要点

  • 首次异基因移植后复发儿童AML的4年总生存概率仅14%。

核心结论

  • 儿童AML首次异基因造血干细胞移植后复发者总体生存极差,4年总生存概率为14%。

研究设计与样本

  • 回顾性I-BFM分析,纳入333例首次异基因造血干细胞移植后复发的儿童急性髓系白血病患者。

主要发现

  • 整体4年总生存概率为14%。
  • 接受第二次移植的患者中,获得与未获得后续缓解者生存相当。

临床怎么用

  • 对于首次异基因移植后复发的儿童AML,应评估是否可行第二次造血干细胞移植以改善生存。
  • 移植物来源和供者选择可能与复发后生存相关,临床决策时可纳入考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Uden T, Bertaina A, Abrahamsson J, et al. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children. Br J Haematol. 2020. PMID: 32012224. doi:10.1111/bjh.16441

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。